Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?

Area of Science:

• Urology
• Oncology

Background:

• Prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.
• Elevated PSA after radical prostatectomy can indicate residual disease or benign prostatic tissue.
• Distinguishing the source of PSA is crucial for patient treatment strategies.

Purpose of the Study:

• To investigate the likelihood of benign prostatic tissue being the source of measurable PSA post-radical prostatectomy.
• To evaluate PSA levels in a cohort of patients with extremely low-risk prostate cancer.

Main Methods:

• A cohort of 1308 men undergoing radical prostatectomy was analyzed.
• 331 patients with extremely low-risk disease (preoperative PSA <10 ng/mL, low Gleason score, etc.) were selected.
• Measurable PSA was defined as 0.05-0.14 ng/mL on two occasions 6 months apart; biochemical recurrence was >0.15 ng/mL.

Main Results:

• In patients with extremely low-risk disease, 0.6% developed measurable PSA and 0.3% had biochemical recurrence.
• Follow-up ranged from 3 months to 6 years (mean 36.2 months).
• The single case of biochemical recurrence responded to salvage radiotherapy, suggesting a malignant origin.

Conclusions:

• Measurable PSA or biochemical recurrence is exceptionally rare in extremely low-risk prostate cancer patients post-prostatectomy.
• Retained benign prostatic elements are unlikely to be the source of elevated PSA in this select group.
• These findings support the interpretation of post-operative PSA elevations as indicative of residual malignancy.